Page 377 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 377
WEDNESDAY, APRIL 22, 2015 18:00 – 19:30
PRO.MED.CS Praha a.s. Strauss 3
Liver and atherosclerosis
Chairs:
Oxana Drapkina, Russia
Vladimir Ivashkin, Russia
Mark Thursz, The United Kingdom
Metabolic syndrome and NAFLD
Mark Thursz, The United Kingdom
Atherosclerosis and the liver
Oxana Drapkina, Russia
Lipid-lowering therapy in patients with high risk of cardiovascular
complications and with liver pathology
Sergey Martsevich, Russia
THURSDAY, APRIL 23, 2015 07:00 – 08:00
AbbVie Hall C (Plenary)
Call to action: what will it take to truly eradicate HCV?
Chair: INDUSTRY INFORMATION
Michael Manns, Germany
Welcome & Introduction
Michael Manns, Germany
How can we work together to eradicate HCV?
Maria Buti, Spain, Massimo Colombo, Italy, Mark Sulkowski, The United States
Q&A and Summary
Michael Manns, Germany
Vienna, Austria • April 22–26, 2015 377
PRO.MED.CS Praha a.s. Strauss 3
Liver and atherosclerosis
Chairs:
Oxana Drapkina, Russia
Vladimir Ivashkin, Russia
Mark Thursz, The United Kingdom
Metabolic syndrome and NAFLD
Mark Thursz, The United Kingdom
Atherosclerosis and the liver
Oxana Drapkina, Russia
Lipid-lowering therapy in patients with high risk of cardiovascular
complications and with liver pathology
Sergey Martsevich, Russia
THURSDAY, APRIL 23, 2015 07:00 – 08:00
AbbVie Hall C (Plenary)
Call to action: what will it take to truly eradicate HCV?
Chair: INDUSTRY INFORMATION
Michael Manns, Germany
Welcome & Introduction
Michael Manns, Germany
How can we work together to eradicate HCV?
Maria Buti, Spain, Massimo Colombo, Italy, Mark Sulkowski, The United States
Q&A and Summary
Michael Manns, Germany
Vienna, Austria • April 22–26, 2015 377